

BIO VIEW LTD.

INTERIM REPORT

AS OF June 30, 2020

TRANSLATION FROM HEBREW ORIGINAL

BIOVIEW LTD.
INTERIM REPORT
(Unaudited)
AS OF June 30, 2020

TABLE OF CONTENTS

	Page
FINANCIAL STATEMENTS – IN NEW ISRAELI SHEKELS (NIS):	
Statement of financial position	F-3
Statement of comprehensive income	F-4
Statement of cash flows	F-5 – F-6

BIO VIEW LTD.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

A s s e t s	June 30		December 31,
	2020	2019	2019
	(Unaudited)		(Audited)
CURRENT ASSETS:			
Cash and cash equivalents	16,250	15,491	18,743
Accounts receivable:			
Trade	2,622	3,282	4,301
Other	348	666	493
Inventory	4,041	4,883	3,923
	23,261	24,322	27,460
NON-CURRENT ASSETS :			
Restricted cash	125	125	125
Long Term Receivables	684	676	690
Intangible asset	-	58	-
ROU Asset	1,955	2,752	2,501
Deferred taxes	5,715	6,385	5,714
Property and equipment - net	651	548	493
	9,130	10,544	9,523
T o t a l a s s e t s	32,391	34,866	36,983
L i a b i l i t i e s a n d e q u i t y			
CURRENT LIABILITIES:			
Accounts payable:			
Down payments	-	940	-
Trade	1,087	1,953	1,329
Other	1,868	2,577	2,878
Royalties to Chief Scientist	-	43	-
Income in advance	2,384	2,935	4,081
Leasing liability	1,100	1,049	1,067
Provision for warranty	326	312	533
	6,765	9,809	9,888
NON-CURRENT LIABILITIES:			
Liability for employee rights upon retirement - net	484	360	517
Income in advance	159	357	206
Leasing liability	868	1,699	1,422
	1,511	2,416	2,145
COMMITMENTS AND CONTINGENT LIABILITIES			
T o t a l l i a b i l i t i e s	8,276	12,225	12,033
EQUITY:			
Ordinary shares	141	141	141
Additional paid-in capital	52,909	52,779	52,878
Warrants	678	641	668
Reserve from currency translation differences	(825)	(604)	(889)
Treasury shares	(428)		
Accumulated deficit	(28,360)	(30,316)	(27,848)
Total equity	24,115	22,641	24,950
Total liabilities and equity	32,391	34,866	36,983

The accompanying notes are an integral part of these financial statements.

BIO VIEW LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Six months ended June 30		Three months ended June 30		Year ended
	2020	2019	2020	2019	December 31,
	(Unaudited)		(Unaudited)		2019
	NIS in thousands				(Audited)
SALES	11,110	15,407	5,656	8,973	35,790
COST OF SALES	4,369	6,736	2,054	3,793	15,523
GROSS PROFIT	6,741	8,671	3,602	5,180	20,267
RESEARCH AND DEVELOPMENT	2,701	3,026	1,108	1,389	5,708
SALES AND MARKETING	2,170	2,408	949	1,220	4,837
GENERAL AND ADMINISTRATIVE	2,345	2,695	1,029	1,363	5,381
OTHER EXPENSES (INCOME, MAINLY Exchange Rate Differences)	3	472	389	191	946
OPERATING PROFIT (LOSS)	(478)	70	127	1,017	3,395
FINANCIAL EXPENSES (INCOME), net	(30)	6	7	5	27
INCOME (LOSS) BEFORE TAXES ON INCOME	(508)	64	120	1,012	3,368
TAXES ON INCOME	(4)	7	4	(40)	843
NET PROFIT (LOSS)	(512)	57	124	1,052	2,525
OTHER COMPREHENSIVE INCOME:					
RESERVE FROM CURRENCY TRANSLATION DIFFERENCES	31	(217)	(104)	(78)	(345)
LIABILITY FROM EMPLOYEE RIGHTS UPON RETIREMENT	33	(9)	(9)	(5)	(166)
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	(448)	(169)	11	969	2,014
	NIS				
BASIC INCOME (LOSS) PER SHARE	(0.04)	(*)	0.01	(0.07)	0.18
DILUTED INCOME (LOSS) PER SHARE	(0.04)	(*)	0.01	(0.07)	0.18

(*) less than 0.01

The accompanying notes are an integral part of these financial statements.

BIO VIEW LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months ended		Three months ended		Year Ended
	June 30,		June 30,		December
	2020	2019	2020	2019	31, 2019
	(Unaudited)		(Unaudited)		(Audited)
	NIS in thousands				
CASH FLOWS FROM OPERATING ACTIVITIES:					
Net cash provided by (used in) operating activities (see Appendix A)	(1,178)	(954)	(242)	(1,551)	2,845
Income tax paid - net	(5)	(144)	4	(130)	(275)
Interest paid for the lease	(30)		(12)		(74)
Net cash provided by (used in) operating activities	<u>(1,213)</u>	<u>(1,098)</u>	<u>(250)</u>	<u>(1,681)</u>	<u>2,496</u>
CASH FLOWS FROM INVESTING ACTIVITIES:					
Restricted Cash	6	(12)	6	(12)	(18)
Acquisition of property and equipment	(275)	(176)	(44)		(208)
Net cash used in investing activities	<u>(269)</u>	<u>(188)</u>	<u>(38)</u>	<u>(12)</u>	<u>(226)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:					
Leasing payments	(522)	(553)	(212)	(281)	(1,047)
Treasury shares	(428)	-	(428)	-	-
Exercise of Employees' Options		7		7	66
Net cash provided by financing activities	<u>(950)</u>	<u>(546)</u>	<u>(640)</u>	<u>(274)</u>	<u>(981)</u>
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,432)	(1,832)	(928)	(1,953)	1,289
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	18,743	18,007	17,251	17,671	18,007
PROFITS (LOSSES) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	(61)	(684)	(73)	(227)	(553)
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	<u>16,250</u>	<u>15,491</u>	<u>16,250</u>	<u>15,491</u>	<u>18,743</u>

The accompanying notes are an integral part of these financial statements

BIO VIEW LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six months ended June 30,		Three months ended June 30,		Year ended December
	2020	2019	2020	2019	31, 2019
	(Unaudited)		(Unaudited)		(Audited)
NIS in thousands					
Appendixes to statement of cash flows:					
(a) Net cash generated by operating activities:					
Income (loss) before taxes on income	(508)	64	120	1,012	3,368
Adjustments in respect of – income and expense not involving cash flows:					
Depreciation and amortization	663	721	337	354	1,402
Options to employees	41	54	13	44	121
Leasing interest	31	33		17	63
Profit (loss) from exchange rate differences	112	172	(178)	51	(316)
	<u>339</u>	<u>1,044</u>	<u>292</u>	<u>1,478</u>	<u>4,638</u>
Changes in operating asset and liability items:					
Decrease (increase) in accounts receivable:					
Trade	1,674	(260)	99	(1,234)	(1,318)
Other	147	(43)	57	18	73
Decrease (increase) in inventory	(91)	(1,018)	368	346	(105)
Increase (decrease) in accounts payable and accruals:					
Down payments	-	842	-	(104)	-
Trade	(244)	414	(305)	(279)	(206)
Other (including provision for warranty)	(1,229)	70	(163)	(124)	669
Decrease in provision for royalties to Chief Scientist	-	(379)	-	(368)	(422)
Deferred income (including long-term liabilities)	(1,774)	(1,624)	(590)	(1,270)	(484)
	<u>(1,517)</u>	<u>(1,998)</u>	<u>(534)</u>	<u>(3,015)</u>	<u>(1,793)</u>
Net cash provided by operating activities	<u>(1,178)</u>	<u>(954)</u>	<u>(242)</u>	<u>(1,537)</u>	<u>2,845</u>
(b) Interest received:	<u>28</u>	<u>46</u>	<u>9</u>	<u>21</u>	<u>86</u>
(c) Non – Cash Financial Activity					
Leasing liability	-	443	-	443	722

The accompanying notes are an integral part of these financial statements